Polmacoxib

Drug Profile

Polmacoxib

Alternative Names: Acelex; CG-100649

Latest Information Update: 18 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CrystalGenomics
  • Class Antirheumatics; Benzene derivatives; Fluorobenzenes; Furans; Nonsteroidal anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action Carbonic anhydrase inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Osteoarthritis

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 12 Jan 2016 Polmacoxib licensed to TR-Pharm for commercialisation in Turkey and Middle East and North Africa region
  • 01 Sep 2015 Launched for Osteoarthritis in South Korea (PO)
  • 12 Aug 2015 Polmacoxib licensed to Dong-A ST for commercialisation in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top